STOCK TITAN
  1. Home
  2. Sec-filings
  3. CURLF
  4. [6-K] Curaleaf Holdings, Inc. Current Report (Foreign Issuer)

Curaleaf (OTCQX: CURLF) buys remaining Four 20 Pharma stake in Germany

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Curaleaf Holdings has completed the buyout of the remaining 45% stake it did not already own in Four 20 Pharma GmbH, making the German medical cannabis producer a wholly owned subsidiary. Four 20 Pharma is fully EU-GMP and GDP licensed and supplies nursing homes, pharmacies, and research institutions across Germany and select European markets.

The acquisition strengthens Curaleaf’s vertically integrated global supply chain, linking cultivation in Portugal and Canada with licensed distribution in Germany to support a seed-to-patient quality model. Curaleaf has also launched the Four 20 brand in the United Kingdom and Poland and plans further international expansion based on Four 20 Pharma’s quality and compliance blueprint.

Positive

  • None.

Negative

  • None.

Insights

Curaleaf makes Four 20 Pharma a fully owned European platform.

Curaleaf Holdings has acquired the remaining 45% of Four 20 Pharma GmbH, turning an important German partner into a wholly owned subsidiary. Four 20 Pharma brings EU-GMP and GDP licences, strong compliance credentials, and a broad German medical cannabis distribution network.

This move consolidates Curaleaf’s European supply chain, connecting cultivation in Portugal and Canada with licensed distribution in Germany. Four 20 Pharma’s established brand and operations, including the “420NATURAL” line and 110 employees, provide a local platform that Curaleaf is already extending into the UK and Poland.

The filing emphasizes strategy rather than deal economics, so financial impact depends on integration and market growth. Future company filings may detail how this full ownership position contributes to revenue, margins, and broader expansion across regulated medical cannabis markets in Europe.

Remaining stake acquired 45% stake Portion of Four 20 Pharma not previously owned, now fully acquired
Four 20 Pharma employees 110 employees Team size at Four 20 Pharma in Paderborn, Germany
Commission file number 333-249081 Curaleaf Holdings SEC file reference in the Form 6-K
Brand launch year 2020 Launch year of Four 20 Pharma’s “420NATURAL” brand in Germany
EU-GMP regulatory
"a fully EU-GMP and GDP licensed German producer and distributor of medical cannabis"
EU‑GMP is a regulatory standard that certifies pharmaceutical and related manufacturing facilities in the European Union meet strict quality and safety rules for producing medicines and medical products. For investors, an EU‑GMP certificate is like a trusted food‑safety rating for a factory: it signals lower regulatory and supply risk, access to EU markets, and greater confidence that products are consistently made to required specifications.
GDP licensed regulatory
"a fully EU-GMP and GDP licensed German producer and distributor of medical cannabis"
vertically integrated financial
"strengthens Curaleaf's vertically integrated, global supply chain"
Vertically integrated describes a company that owns and controls multiple steps in making and selling its products or services — for example sourcing raw materials, manufacturing, and distribution. Like a bakery that grows its own wheat, mills the flour, bakes the bread and runs the shops, this setup can lower costs, improve quality and speed to market and protect profit margins, but it also requires more capital and can reduce flexibility.
forward-looking statements regulatory
"This media advisory contains forward-looking statements and forward-looking information"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
annual information form regulatory
"under "Risk Factors and Uncertainties" in the Company's latest annual information form"
A company's annual information form is a comprehensive regulatory filing that lays out its business description, key assets, risks, legal matters and other background details shareholders need to understand the company’s operations. Think of it as a detailed owner’s manual or dossier that supplements financial statements, helping investors do deeper homework on how the business works and what could affect its future performance.
Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of April, 2026
Commission File Number: 333-249081
Curaleaf Holdings, Inc.
(Name of Registrant)
666 Burrard Street, Suite 1700,
Vancouver, British Columbia V6C 2X8, Canada
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☐    Form 40-F ☒


SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
CURALEAF HOLDINGS, INC.
(Registrant)
Date:
April 30, 2026
By:
/s/ Peter Clateman
Name:
Peter Clateman
Title:
Chief Legal Officer


EXHIBIT INDEX

Exhibit Number
Description
99.1
Press Release

Curaleaf Holdings, Inc. Investor Relations Curaleaf Completes Buyout of Remaining Stake in Germany's Four 20 Pharma STAMFORD, Conn., April 30, 2026 /PRNewswire/ -- Curaleaf Holdings, Inc (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, has completed the buyout of the remaining 45% stake not previously owned in Four 20 Pharma GmbH, a fully EU-GMP and GDP licensed German producer and distributor of medical cannabis. Four 20 Pharma is recognized for its high-quality cultivation, pharmaceutical-grade processing, and comprehensive distribution network across Germany and select European markets, serving nursing homes, pharmacies, and research institutions. The company's commitment to compliance, patient care, and scientific rigor positions it as a cornerstone of Europe's medical cannabis ecosystem. The full acquisition of Four 20 Pharma strengthens Curaleaf's vertically integrated, global supply chain, from owned cultivation sources in Portugal and Canada through to licensed distribution across Germany, delivering a true seed-to-patient quality guarantee and full oversight at every stage. Since the initial agreement in 2022, Curaleaf and Four 20 Pharma have collaborated closely to expand patient access, advance research initiatives, and streamline the international medical cannabis supply chain, validating a data-driven approach to education, cultivation, and product development. "Completing this buyout of the remaining stake in Four 20 Pharma reinforces our commitment to Europe and underscores the strategic importance of building high-quality, locally anchored operations in a market that will continue to grow exponentially," said Boris Jordan, CEO and Chairman of Curaleaf. "Four 20 Pharma's leadership in production, compliance, and distribution allows us to expand patient access to medical cannabis while driving innovation across the international market. This investment has been a meaningful, strategic anchor in our international strategy, and we're looking forward to continued long- term growth in Europe." "Joining the Curaleaf family as a fully integrated subsidiary marks an exciting new chapter for Four 20 Pharma," said Torsten Greif, Founder and Managing Director of Four 20 Pharma. "We built this company on an uncompromising commitment to quality, compliance, and patient care, values that align perfectly with Curaleaf's international mission. Together, we are uniquely positioned to set the standard for medical cannabis across regulated markets worldwide." Building on Four 20 Pharma's success in Germany, Curaleaf has already launched the Four 20 brand in the United Kingdom and Poland and intends to continue expanding the brand across additional international markets, leveraging the blueprint of quality and compliance that has made Four 20 Pharma one of Germany's most trusted medical cannabis brands. The partnership reflects Curaleaf's broader international strategy of combining local expertise with global scale to build the world's leading international cannabis company. For more information on Curaleaf and its operations, visit https://curaleaf.com/ About Curaleaf Holdings Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf") is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, Find, Dark Heart, and Anthem provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is powered by a strong presence in all stages of the supply chain. Its unique distribution network throughout Europe, Canada and Australasia brings together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com. About Four 20 Pharma GmbH Four 20 Pharma GmbH is a leading, fully EU-GMP & GDP licensed European producer and distributor of medical cannabis with industry-leading product quality and best-in-class regulatory expertise. Four 20 Pharma entered the German market with the vision to guarantee continuous patient care, and since the launch in 2020 of its "420NATURAL" brand, the company has created a steady supply chain to deliver the best possible cannabis products to its patients. The company employs 110 team members and is based in Paderborn, Germany. Forward Looking Statements This media advisory contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans", "expects" or "proposed", "is expected", "intends", "anticipates", or "believes", or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward-looking statements and information concerning the acquisition of Four 20 Pharma. Such forward- looking statements and information reflect management's current beliefs and are based on assumptions made by and

 

information currently available to the company with respect to the matter described in this new release. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information about these assumptions and uncertainties is contained under "Risk Factors and Uncertainties" in the Company's latest annual information form filed on February 26, 2026, which is available under the Company's SEDAR profile at http://www.sedar.com, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Toronto Stock Exchange has not reviewed, approved or disapproved the content of this news release. Investor Contact: Curaleaf Holdings, Inc. Camilo Lyon, Chief Investment Officer IR@curaleaf.com Media Contact: MATTIO Communications MattioCuraleaf@Mattio.com Four 20 Pharma GmbH Media Contact: Oliver Kirch 420pharma@heyst.com SOURCE Curaleaf Holdings, Inc. https://ir.curaleaf.com/2026-04-30-Curaleaf-Completes-Buyout-of-Remaining-Stake-in-Germanys-Four-20-Pharma

 

Source: View Original Filing on SEC EDGAR

FAQ

What did Curaleaf Holdings (CURLF) announce in its April 2026 Form 6-K?

Curaleaf announced it completed buying the remaining 45% stake in Four 20 Pharma GmbH, making the German medical cannabis producer a wholly owned subsidiary and strengthening Curaleaf’s vertically integrated European medical cannabis supply chain.

How much of Four 20 Pharma did Curaleaf Holdings (CURLF) acquire?

Curaleaf acquired the remaining 45% stake in Four 20 Pharma GmbH that it did not already own. This buyout turns Four 20 Pharma into a fully owned subsidiary and consolidates Curaleaf’s control over a key German medical cannabis platform.

What is Four 20 Pharma GmbH, the company Curaleaf now fully owns?

Four 20 Pharma GmbH is a fully EU-GMP and GDP licensed German producer and distributor of medical cannabis. It focuses on high-quality cultivation, pharmaceutical-grade processing, and distribution to nursing homes, pharmacies, and research institutions across Germany and select European markets.

How does the Four 20 Pharma acquisition support Curaleaf’s European strategy?

The acquisition strengthens Curaleaf’s vertically integrated, seed-to-patient supply chain from cultivation in Portugal and Canada to licensed distribution in Germany. It also supports expansion of the Four 20 brand into the UK, Poland, and additional international markets under a quality- and compliance-focused model.

In which markets is the Four 20 Pharma brand already present under Curaleaf?

Building on Four 20 Pharma’s success in Germany, Curaleaf has launched the Four 20 brand in the United Kingdom and Poland. The company intends to extend the brand into further international markets using the same quality and compliance framework that built its German reputation.

How large is Four 20 Pharma GmbH within Curaleaf’s operations?

Four 20 Pharma employs about 110 team members and is based in Paderborn, Germany. It operates a steady medical cannabis supply chain and its “420NATURAL” brand, making it a central part of Curaleaf’s European medical cannabis ecosystem and international growth strategy.

Filing Exhibits & Attachments

1 document

Press Releases